Skip to main content
Clinical Trials/DRKS00020994
DRKS00020994
Completed
Phase 2

Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

niversitätsklinikum Regensburg0 sites20 target enrollmentStarted: March 10, 2020Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
niversitätsklinikum Regensburg
Enrollment
20

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • o Age at least 18 years
  • o confirmed diagnosis of Osler's disease based on the Curacao criteria
  • o Written consent to the clinical trial
  • o Intellectual and linguistic ability to answer a questionnaire independently
  • o At least 2 TruBlue laser treatments in the area of the nasal mucosa
  • o Bleeding frequency more often than once a week and of which at least more than 5 minutes

Exclusion Criteria

  • o Existing pregnancy (ß\-HCG test is performed)
  • o Participation in another clinical trial
  • o Bronchial asthma or chronic obstructive pulmonary disease (COPD)
  • o Sinus bradycardia, Sick\-sinus syndrome, second\- or third\-degree Sinuatrial block, AV block without pacemaker in history and eCG prior to clinical trial
  • o manifest heart failure, cardiogenic shock, angina pectoris in anamnesis
  • o Hypotension below 100/60 mmHg in the anamnesis and in pre\-clinical trial examination
  • o Bradycardia (less than 60 beats per minute) in the ECG prior to the start of clinical trials
  • o Patients with severe peripheral circulatory disorders/diseases (e.g. severe forms of Raynaud's disease or Raynaud's syndrome) in the anamnesis
  • o Diabetes mellitus in the anamnesis
  • o Thyroid overfunction in anamnesis

Investigators

Sponsor
niversitätsklinikum Regensburg

Similar Trials